Advertisement

Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels

  • Alex M. EbiedEmail author
  • Tammy Li
  • Samantha F. Axelrod
  • Douglas J. Tam
  • Yiqing Chen
Article
  • 68 Downloads

Abstract

There is limited guidance on intravenous dosing of unfractionated heparin in obese patients. The purpose of this study was to determine the efficacy and safety of a standard unfractionated heparin (UFH) protocol in obese patients based on total body weight (TBW) or adjusted body weight (ABW) to reach two consecutive therapeutic anti-Xa levels. This was a retrospective observational cohort study conducted in a large academic medical center. Adults received a standard UFH protocol between January 1, 2013 to December 31, 2015. Inclusion criteria included age ≥ 18 years of age, weight ≥ 100 kg with a BMI ≥ 30 kg/m2, and received intravenous UFH. Patients were excluded if they received an alternative UFH protocol, received < 24 h of the standard UFH protocol, or had inadequate compliance to protocol. Out of the 131 patients included, 109 patients reached two consecutive therapeutic UFH levels within 96 h. The average time to two consecutive therapeutic UFH levels was 29.4 h and 27.6 h in patients dosed by TBW and ABW, respectively (95% CI − 4.63 to 8.11; P = 0.93). Safety outcomes included major bleeding, overt bleeding, or death events between patients dosed by TBW compared to ABW, (p = 0.61, p = 1.0, p = 1.0, respectively). Dosing intravenous UFH based on TBW or ABW resulted in similar times to therapeutic anti-Xa levels and safety outcomes. The data provided suggests using either TBW or ABW in obese patients is as effective and safe to use.

Keywords

Anticoagulation Heparin Obesity Pharmacokinetics Drug safety Therapeutic monitoring 

Notes

Funding

None to disclose.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article

References

  1. 1.
    Pfizer. Heparin Sodium Injection package insert. New York, NY; 2016Google Scholar
  2. 2.
    Centers for Disease Control and Prevention. Defining adult overweight and obesity (April 2017). https://www.cdc.gov/obesity/adult/defining.html (accessed 2019 Feb 1)
  3. 3.
    Hales CM, Carroll MD, Fryar CD, Ogden CL (2017) Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. 1–8Google Scholar
  4. 4.
    Holst AG, Jensen G, Prescott E (2010) Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 121:1896–1903CrossRefGoogle Scholar
  5. 5.
    Floroff CK, Palm NM, Steinberg DH, Powers ES, Wiggins BS (2017) Higher maximum doses and infusion rate compared with standard unfractionated UFH therapy are associated with adequate anticoagulation without increased bleeding in both obese and non-obese patients with cardiovascular indication. Pharmacotherapy 37(4):393–400CrossRefGoogle Scholar
  6. 6.
    Estes JW (1980) Clinical pharmacokinetics of heparin. Clin Pharmacokinet 5:204–220CrossRefGoogle Scholar
  7. 7.
    Schaefer DC, Hufnagle J, Williams L (1996) Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician 54:2517–2521Google Scholar
  8. 8.
    Riney JN, Hollands J, Smith JR, Deal EN (2010) Identifying optimal initial infusion rates for unfractionated UFH in morbidly obese patients. Ann Pharmacother 44:1141–1151CrossRefGoogle Scholar
  9. 9.
    Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus anti-factor Xa UFH assay in monitoring unfractionated UFH by continuous intravenous infusion. Ann Pharmacother 45(7–8):861–868CrossRefGoogle Scholar
  10. 10.
    Rosenberg AF, Zumberg M, Taylor L, Leclaire A, Harris N (2010) The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract 23(3):210–216CrossRefGoogle Scholar
  11. 11.
    Garcia D, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants- antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest 141:e24S–e43SCrossRefGoogle Scholar
  12. 12.
    Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK (2016) Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 41(1):165–186CrossRefGoogle Scholar
  13. 13.
    Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. Ann Intern Med 119:874–881CrossRefGoogle Scholar
  14. 14.
    Fan J, John B, Tesdal E (2016) Evaluation of UFH dosing based on adjusted body weight in obese patients. Am J Health Syst Pharm 73:1512–1522CrossRefGoogle Scholar
  15. 15.
    Isherwood M, Murphy ML, Bingham AL, Siemianowski LA, Hunter K, Hollands JM (2017) Evaluation of safety and effectiveness of standardized anti-factor Xa-based unfractionated UFH protocols in obese versus non-obese patients. J Thromb Thrombolysis 43(4):476–483CrossRefGoogle Scholar
  16. 16.
    Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during UFH treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568CrossRefGoogle Scholar
  17. 17.
    Hylek EM, Regan S, Henault LE et al (2003) Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 163:621–627CrossRefGoogle Scholar
  18. 18.
    Hosch LM, Breedlove EY, Scono LE, Knoderer CA (2017) Evaluation of an unfractionated UFH pharmacy dosing protocol for the treatment of venous thromboembolism in nonobese, obese, and severely obese patients. Ann Pharmacother 51(9):768–773CrossRefGoogle Scholar
  19. 19.
    Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747CrossRefGoogle Scholar
  20. 20.
    Spruill WJ, Wade WE, Huckaby WG, Leslie RB (2001) Achievement of anticoagulation by using a weight-based UFH dosing protocol for obese and nonobese patients. Am J Health- Syst Pharm 58:2143–2146CrossRefGoogle Scholar
  21. 21.
    Yee WP, Norton LL (1998) Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 55:159–162CrossRefGoogle Scholar
  22. 22.
    Hohner EM, Kruer RM, Gilmore VT, Streiff M, Gibbs H (2015) Unfractionated UFH dosing for therapeutic anticoagulation in critically ill obese adults. J Crit Care 30(2):395–399CrossRefGoogle Scholar
  23. 23.
    Gerlach AT, Folino J, Morris BN, Murphy CV, Stawicki SP, Cook CH (2013) Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 3(3):195–199CrossRefGoogle Scholar
  24. 24.
    Shin S, Harthan EF (2015) Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagul Fibrinolysis 26:655–660Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacotherapy and Translational ResearchUniversity of Florida College of PharmacyGainesvilleUSA
  2. 2.Data Management Analyst IIUniversity of Florida College of PharmacyGainesvilleUSA

Personalised recommendations